Hybrid PET-MR imaging for characterizing arrhythmogenic cardiomyopathies
Tissue and Metabolic Characterization of Arrhythmogenic Cardiomyopathies by Hybrid PET-MRI Imaging, Impact of the Observed Profiles on the Phenotype and on the Evolution of Cardiomyopathy
This study is testing a new imaging tool to see if it can help doctors better understand the heart issues in patients with arrhythmogenic cardiomyopathies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 16 Years to 99 Years |
| Sex | All |
| Sponsor | Nantes University Hospital Academic / other |
| Locations | 5 sites (Angers and 4 other locations) |
| Trial ID | NCT05450783 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of a new hybrid PET-MR imaging tool in characterizing tissue and metabolic profiles of patients with arrhythmogenic cardiomyopathies (AC). By enrolling 80 patients with genetic AC, the study will assess the impact of myocardial inflammation on the phenotype and progression of the disease. The research will also explore associated immunological mechanisms and correlate findings with existing anatomical data. This approach seeks to provide a non-invasive method for understanding the disease better and improving patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals over 16 years old diagnosed with genetic arrhythmogenic cardiomyopathies.
Not a fit: Patients with left or biventricular AC carrying specific pathogenic gene variants or those with autoimmune diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and prognostic tools for patients with arrhythmogenic cardiomyopathies.
How similar studies have performed: While the use of PET-MR imaging in inflammatory conditions has shown promise, this specific application in arrhythmogenic cardiomyopathies is novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female over 16 years old Exclusion Criteria: * Patients and their relatives with left ventricular or biventricular AC and carrier of a pathogenic or likely pathogenic variant in one of the following genes : PKP2, DSG2, DSC2, JUP, DSP, DES, FLNC, PLN, LMNA, TMEM43, CDH2, BAG3, RYR2, RBM20 Consent form Exclusion Criteria : * Sarcoidosis or known or diagnosed autoimmune disease * History of myocardial infarction * Patient under guardianship, curatorship or safeguard of justice
Where this trial is running
Angers and 4 other locations
- CHU Angers — Angers, France (Recruiting)
- CHU Brest — Brest, France (Recruiting)
- CHU de Nantes — Nantes, France (Recruiting)
- AP-HP La Salpêtrière — Paris, France (Recruiting)
- CHU de Rennes — Rennes, France (Recruiting)
Study contacts
- Principal investigator: Nicolas Piriou, PH — Nantes University Hospital
- Study coordinator: Nicolas Piriou, PH
- Email: nicolas.piriou@chu-nantes.fr
- Phone: 0253482781
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.